Drug Interactions between leniolisib and ubrogepant
This report displays the potential drug interactions for the following 2 drugs:
- leniolisib
- ubrogepant
Interactions between your drugs
ubrogepant leniolisib
Applies to: ubrogepant and leniolisib
Leniolisib can increase the blood levels of ubrogepant. This may increase side effects such as nausea and sleepiness. The usual recommended dose for migraine is 50 mg in individuals who are receiving treatment with leniolisib. A second dose, if needed, may be taken 2 hours after the initial dose. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a different dose to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ubrogepant food
Applies to: ubrogepant
Grapefruit and grapefruit juice can increase the blood levels of ubrogepant. This may increase side effects such as nausea and sleepiness. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe an alternative that does not interact, or you may need a different dose to safely use your medication with grapefruit and grapefruit juice. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
leniolisib food
Applies to: leniolisib
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with inhibitors of CYP450 3A4 including grapefruit or grapefruit juice may increase the plasma concentrations of leniolisib, which undergoes extensive CYP450 3A4-mediated first-pass metabolism in the gut wall and liver. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.
MANAGEMENT: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of leniolisib. Some authorities recommend to avoid grapefruit products during leniolisib treatment (UK).
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.